Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | NOX1 | Q9Y5S8 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10591086 | 0.84 | NOX1 (0.50) | MAPTKMT2AMAPK1GAANOX1 | |
| SCHEMBL12812969 | 0.83 | CA9 (0.33) | MAPTMEN1KMT2AGAANOX1 | |
| SCHEMBL3112042 | 0.82 | MAPT (0.36) | EPHX2MAPTMEN1KMT2AHSD17B10 | |
| SCHEMBL10591060 | 0.82 | SNCA (0.55) | MAPTMEN1KMT2AMAPK1GAA | |
| SCHEMBL16061005 | 0.81 | NOX1 (0.43) | MAPTKMT2AALOX15HSD17B10GAA | |
| SCHEMBL87790 | 0.80 | GAA (0.47) | MAPTMEN1KMT2AALOX15HSD17B10 | |
| SCHEMBL12273545 | 0.79 | MEN1 (0.35) | MAPTMEN1KMT2AALOX15HSD17B10 | |
| SCHEMBL10593297 | 0.79 | EPHX2 (0.47) | EPHX2MAPTMEN1KMT2AALOX15 | |
| SCHEMBL12272774 | 0.78 | ALDH1A1 (0.34) | MAPTMEN1KMT2AALOX15HSD17B10 | |
| SCHEMBL12272572 | 0.78 | ALDH1A1 (0.37) | MAPTMEN1KMT2AALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868711-B2 | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160228491-A1 | THERAPEUTIC COMPOSITIONS INCLUDING PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES AND USES THEREOF | STEALTH PEPTIDES INTERNATIONAL, INC. (MC) | 2016-08-11 | — | — | US | disclosed |
| US-20160039776-A1 | PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20140275045-A1 | PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | EDISON PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| EP-0115394-B1 | PHENOTHIAZONE DERIVATIVES AND ANALOGS | MERCK FROSST CANADA INC. (CA) | 1989-06-28 | — | — | EP | disclosed |
| EP-0155623-A2 | Use of lipoxygenase inhibitors for the preparations of cytoprotective pharmaceutical compostions and process for the preparation of a cytoprotective pharmaceutical composition | MERCK & CO. INC. (US) | 1985-09-25 | — | — | EP | disclosed |
| EP-0115394-A2 | Phenothiazone derivatives and analogs | MERCK FROSST CANADA INC. (CA) | 1984-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275045-A1 | PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PCK2, MGST3, TXNRD2 | EPHX2 4651/4885MAPT 199/4885MEN1 4475/4885 |
| US-20160039776-A1 | PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PCK2, MGST3, TXNRD2 | EPHX2 4651/4885MAPT 199/4885MEN1 4475/4885 |
| US-20160228491-A1 | THERAPEUTIC COMPOSITIONS INCLUDING PHENAZINE-3-ONE AND PHENOTHIAZINE-3-ONE DERIVATIVES AND USES THEREOF | TYR, DNPEP, ARG2 | EPHX2 4198/4885MAPT 76/4885MEN1 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.